Halozyme Therapeutics, Inc.

Filing receipts

“The increase in cost of sales was primarily due to an increase in bulk rHuPH20 sales.”

“The increase in SG&A expenses was primarily due to an increase in consulting and professional service fees, including litigation costs in connection with a patent infringement litigation case, the acquisition of Elektrofi and Surf Bio, and an increase in compensation expense.”

“Product Sales, Net – Product sales, net were as follows (in thousands): Three Months Ended Increase / (Decrease) March 31, 2026 2025 Dollar Percentage Proprietary product sales $ 41,873 $ 36,341 $ 5,532 15 % Bulk rHuPH20 sales 73,497 27,025 46,472 172 % Device partnered product sales 15,054 14,675 379 3 % Total product sales, net $ 130,424 $ 78,041 $ 52,383 67 % The increase in product sales, net was primarily due to increased sales of bulk rHuPH20 driven by partner demand as well as contributions from our proprietary product XYOSTED driven by continued market growth.”